FIR Filed Against Aarav Pharma for Allegedly Supplying Spurious Snake Anti-Venom to Goa Health Department
Goa Police have registered a First Information Report (FIR) against Mumbai-based Aarav Pharma for allegedly supplying spurious snake anti-venom to the Directorate of Health Services (DHS), Goa. The case has sparked serious concerns about drug safety, regulatory oversight, and procurement procedures within the public healthcare system.
1,080 Vials Seized Before Use
According to health officials, the complaint was filed by the Deputy Director of Medicine at DHS after irregularities were detected in a consignment of anti-snake venom supplied to the department. The stock, worth approximately ₹4.9 lakh, consisted of 1,080 vials intended for distribution across government hospitals and primary health centres.
Upon identifying discrepancies, authorities immediately quarantined and seized the entire batch from the DHS medical store depot. Officials have confirmed that none of the suspected vials were administered to patients, preventing any potential public health risk.
Alleged Mislabeling and Branding Concerns
Preliminary inquiries suggest that the supplied anti-venom allegedly carried packaging and labeling resembling that of a recognized pharmaceutical manufacturer. Authorities suspect that unauthorized branding may have been used to present the product as genuine.
The seized samples have been sent for laboratory analysis to verify their composition, authenticity, and compliance with safety standards. The outcome of these tests will be crucial in determining the nature and seriousness of the alleged violations.
FDA Issues Show-Cause Notice
Parallel to the criminal investigation, the Food and Drugs Administration (FDA) has initiated regulatory proceedings against Aarav Pharma. A show-cause notice has been issued to the company, asking why its drug license should not be suspended or cancelled under provisions of the Drugs and Cosmetics Act, 1940.
The notice reportedly seeks clarification regarding the procurement source, manufacturing details, and supply chain documentation related to the anti-venom consignment.
Court Denies Interim Relief
In a recent development, Aarav Pharma approached the court seeking interim relief to halt regulatory action. However, the court declined to grant temporary protection, allowing investigative and enforcement proceedings to continue without interruption.
Legal experts state that denial of interim relief indicates that authorities may proceed with scrutiny and potential action based on the findings of the investigation.
Public Health Implications
Snake anti-venom is a life-saving biological product used to treat venomous snake bites. India reports thousands of snakebite cases annually, particularly during the monsoon season. Timely access to genuine, properly stored anti-venom is critical to prevent severe complications and fatalities.
Health authorities have emphasized that patient safety remains uncompromised. Verified stocks of anti-venom are reportedly available across state-run healthcare facilities to ensure uninterrupted treatment.
Investigation Ongoing
The investigation is currently focused on tracing the supply chain and identifying whether additional entities or intermediaries were involved. Authorities are also reviewing procurement documents, tender processes, and supplier credentials to determine accountability.
If proven, supplying counterfeit or substandard medicines especially life-saving drugs could attract serious penalties under criminal and drug control laws.
Officials have assured the public that strict monitoring mechanisms are in place and that corrective measures will be implemented to strengthen safeguards within the health procurement system. Further updates are expected as laboratory results and investigative findings become available.
